Georgetown University Law Center

Scholarship @ GEORGETOWN LAW

2018

Requiring Human Papilloma Virus Vaccination for School Entry
Michelle J. Bayefsky
Harvard Medical School, Michelle_Bayefsky@hms.harvard.edu

Lawrence O. Gostin
Georgetown University Law Center, gostin@law.georgetown.edu

This paper can be downloaded free of charge from:
https://scholarship.law.georgetown.edu/facpub/2117
https://ssrn.com/abstract=3309890

JAMA Pediatrics
This open-access article is brought to you by the Georgetown Law Library. Posted with permission of the author.
Follow this and additional works at: https://scholarship.law.georgetown.edu/facpub
Part of the Health Law and Policy Commons

Opinion

VIEWPOINT

Michelle J. Bayefsky,
BA
Harvard Medical
School, Boston,
Massachusetts.
Lawrence O. Gostin,
JD
O’Neill Institute for
National and Global
Health Law,
Georgetown University
Law Center,
Washington, DC.

JAMA Pediatrics
Patient Page

Corresponding Author:
Lawrence O. Gostin, JD,
O’Neill Institute for
National and Global
Health Law, Georgetown
University Law Center,
600 New Jersey Ave,
NW, Washington, DC
20001 (gostin
@law.georgetown.edu).

Requiring Human Papilloma Virus Vaccination
for School Entry
The Centers for Disease Control and Prevention (CDC)
estimates that 41 000 people are diagnosed as having a
humanpapillomavirus(HPV)–associatedcancereachyear,
amounting to almost 2.5% of all new cancer diagnoses.1
For men, the most common associated cancer is oropharyngeal cancer, and for women, it is cervical cancer.
More than 250 000 women in the United States live with
cervical cancer, and one-third will die within 5 years of
diagnosis.2 The incidence of cervical cancer has declined
considerably since the development of Papanicolaou
test screening, but the percentage of women undergoing
Papanicolaou tests has decreased since 2000. Furthermore, screening has been inequitably distributed across
populations; women insured through Medicaid or without
health coverage and women with lower education levels
are screened at lower rates.3 Screening for other HPVassociated cancers such as oropharyngeal cancer, anal
cancer, vaginal cancer, vulvar cancer, and penile cancer is
much less robust. Thus, while screening is an effective
prevention tool, the ultimate public health success would
be to prevent HPV infection altogether.
Preventing HPV infection is precisely the goal of HPV
vaccination. The US Food and Drug Administration first
approved of the vaccine for children and young adults
in 2006 and recently expanded approval to include
adults up to age 45 years. Currently, the CDC recommends HPV vaccination for boys and girls aged 11 and 12
years, as well as women through age 26 years and men
through age 21 years who were not previously vaccinated. These recommendations might change given
the new expanded US Food and Drug Administration
approval. Despite strong evidence of safety and effectiveness, vaccination rates have been disappointingly
low. In 2016, only 43% of adolescents were up to date
on recommended HPV doses2 compared with 81.3% for
meningococcal strains ACWY; 86.1% for varicella; 86.4%
for tetanus, diphtheria, and pertussis; 90.7% for measles,
mumps, and rubella; and 91.1% for hepatitis B.4 The
highly discrepant vaccination rates stem largely from the
fact that HPV vaccination is not uniformly required for
school entry, while the other childhood vaccines are
required. Only 2 states (Virginia and Rhode Island) and
Washington, DC, require HPV vaccination for school
entry, and Virginia has a generous opt-out provision.
When the US Food and Drug Administration initially
approved HPV vaccination, it was not mandated for 2 primary reasons. The vaccine was too new for long-term
safety and effectiveness studies. Further, since the vaccine was approved only for girls, a mandate could be
discriminatory. Neither of these concerns is now applicable; the vaccine is approved for both sexes, and 90
million doses over 10 years has amply demonstrated the
vaccine’s safety and effectiveness.5
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Resistance to mandating the vaccine now centers
on the fact that HPV is sexually transmitted, with
some parents wanting autonomy to make decisions
for their child regarding what they view as a sensitive
subject. Furthermore, some question whether mandatory vaccination can be justified for a disease that is
not easily transmissible in the school setting. These
critiques cast doubt on the necessity of vaccinating all
school-aged children since the harms of HPV materialize much later in life.
We believe these arguments against mandating HPV
vaccination are flawed and offer 4 reasons why the HPV
vaccine should be urgently mandated. First, HPV vaccination is in the child’s best interests. As outlined above,
HPV is a major cause of cancer-related morbidity and
mortality; given the ubiquity of the virus, individuals
engaged in sexual activity are at significant risk. The CDC
recommends vaccination at a young age because children should be immunized before they are sexually
active and exposed to the virus. A significant minority of
young teenagers engage in sexual activity (18% of boys
and 13% of girls by age 15 years).6 Moreover, there is no
moral or public health significance to the argument that
vaccines should be required only against diseases immediately transmissible in the school setting. For example,
hepatitis B vaccination is required, even though it is transmitted perinatally, sexually, through shared drug injection equipment, or through direct contact with blood.
Second, while parents should be afforded considerable autonomy in raising their children, law and
ethics do not support parents making health-related
decisions that are contrary to their child’s best interests.7
Parental autonomy has clear limits that include making
decisions that can harm the child’s health and safety.
In the case of HPV vaccination, the future benefits to children far outweigh the limits on parental rights. Requiring a highly safe and effective vaccine is a relatively
minor intrusion on parental autonomy compared with
the considerable importance of avoiding a tangible risk
of cancer. Parents, moreover, may underestimate the
health consequences of resisting HPV vaccination, or
they may oppose vaccination nonetheless. In either case,
the child’s health should take precedence.
Third, HPV vaccination is a form of social solidarity.8
The ethical/legal underpinning of mandatory vaccination is about controlling dangerous infections for the
public good. Society values each individual child but also
whole communities and populations. Widespread
vaccination campaigns can establish community or
“herd” immunity, reducing childhood diseases to very
low levels. Rather than focusing exclusively on individual benefits, we should also strive to protect our
neighbors from disease and benefit the public at large.
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Public benefits include the avoidance of morbidity and
mortality but also limiting the costs of cancer treatment and the
lost productivity of those experiencing HPV-associated disease. The
annual burden of preventing and treating HPV-associated disease
in the United States has been estimated to be $8 billion,9 which is
far less than the estimated annual cost of administering approximately 8 million doses of the HPV vaccine (2 doses to 4 million
children aged 11 years): $1.6 billion. Furthermore, studies have
demonstrated that HPV vaccination is cost effective in a range of
low-income to high-income countries, such as Germany.10
Finally, mandating vaccination will bring greater health equity
with respect to HPV-associated disease. Specifically, black and
Hispanic women have long had poorer outcomes from cervical cancer, which is largely due to disparities in access to cancer screening
(especially for Hispanic women) and the quality of cancer treatment. Similar inequities burden women without health insurance and
those with lower education levels. Disadvantaged and minority
women will therefore benefit most from widespread vaccination,
which is best accomplished with mandates tied to school entry.
To demonstrably improve outcomes for those most vulnerable to
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